Recently, it is also shown that SREBP-2 could stimulate the gene transcription of HMG-CoA reductase, indicating another molecular mechanism whereby dysfunctional thyroid regulates the pathological development of dyslipidemia [18]. Here, SREBF2 is linked to metabolic syndrome.